Mammalian DNA (cytosine-5) methyltransferases (DNMT) have roles in the establishment and regulation of the transcriptome by methylating DNA. DNMTs are attractive cancer therapy targets with numerous clinical trials ongoing. Dnmt1 plays a role in the establishment and regulation of tissue-specific patterns of methylated cytosine residues. In the context of embryonic development, imprinting, and X-chromosome inactivation, Dnmt3A and 3B are thought to function in de novo methylation, rather than maintenance methylation. Researchers are exploring the expression levels of these DNMTs and their resulting tissue-specific methylation patterns as possible biomarkers for various cancers and developmental abnormalities.
New England Biolab's human Dnmt1 (NEB #M0231), Dnmt3A (NEB #M0229) and Dnmt3B (NEB #M0232) antibodies are each validated for Western blot. The Human Dnmt3B antibody also works well for immunoprecipitation.